Welcome to our dedicated page for Alpha Tau Medical Ltd. Warrant news (Ticker: DRTSW), a resource for investors and traders seeking the latest updates and insights on Alpha Tau Medical Ltd. Warrant stock.
Alpha Tau Medical focuses on research, development, and commercialization of Alpha DaRT for solid cancer tumor treatment. Utilizing alpha radiation, Alpha DaRT aims to provide highly potent and conformal radiotherapy by treating solid tumors with interstitial radioactive seeds.
Rhea-AI Summary
Alpha Tau Medical Ltd. has entered into a long-term lease agreement for a standalone building in Hudson, New Hampshire, to establish its second U.S. manufacturing site. The new site will be larger than the existing site in Lawrence, Massachusetts, and is expected to support the company's goals of scaling up capacity and achieving manufacturing redundancy. The company plans to initiate manufacturing of Alpha DaRT treatments at the Hudson facility within two years, with a capacity of nearly 1.8 million Alpha DaRT sources per year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.52%
Tags
-
Rhea-AI Summary
Alpha Tau Medical announces that former FDA Commissioner Dr. Stephen M. Hahn has joined its Scientific Advisory Board. Dr. Hahn's expertise will be valuable as the company advances its Alpha DaRT technology towards FDA clearance and explores new indications for cancer treatment.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.11%
Tags
-
Rhea-AI Summary
Alpha Tau Medical announces successful treatment of patient with advanced inoperable pancreatic cancer using Alpha DaRT therapy
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.3%
Tags
News
Rhea-AI Summary
Alpha Tau Medical reports positive outcomes in feasibility trials and receives land grant for future headquarters
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.08%
Tags
-
Rhea-AI Summary
Alpha Tau Medical Ltd. to participate in investor conferences
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.49%
Tags
-
Rhea-AI Summary
Initial long-term safety and tumor control outcomes for patients treated with Alpha DaRT showed 89% complete response rate and 77% two-year local recurrence-free survival rate. No grade 3 or higher acute or late toxicities observed.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.78%
Tags
Rhea-AI Summary
Alpha Tau Medical Ltd. (NASDAQ: DRTS, DRTSW) announces that Raphi Levy, Chief Financial Officer, will present at the Emerging Growth Conference on August 9th, 2023, to discuss the innovative alpha-radiation cancer therapy Alpha DaRT™. The event will take place virtually, with an archived webcast available for those unable to attend live.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.32%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.56%
Tags
-
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.5%
Tags
Rhea-AI Summary
Alpha Tau Medical has announced the treatment of the first patient in a feasibility and safety study of its alpha-radiation cancer therapy, Alpha DaRT, for the treatment of squamous cell carcinoma of the vulva. The trial aims to recruit 10 participants and will assess safety, feasibility, efficacy, and patient outcomes. This trial is part of Alpha Tau's strategy to expand the use of Alpha DaRT in other hard-to-treat indications.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.99%
Tags
FAQ
What is the current stock price of Alpha Tau Medical Ltd. Warrant (DRTSW)?
The current stock price of Alpha Tau Medical Ltd. Warrant (DRTSW) is $0.176 as of November 1, 2024.
What is Alpha Tau Medical Ltd. focused on?
Alpha Tau Medical is focused on research, development, and commercialization of Alpha DaRT for treating solid cancer tumors.
What technology does Alpha DaRT utilize?
Alpha DaRT uses alpha radiation to deliver highly potent and conformal radiotherapy to solid tumors.
What are the primary goals of Alpha DaRT technology?
The primary goals include treating solid tumors with interstitial radioactive seeds that release short-lived alpha emitting atoms into the tumor.
What recent achievements has Alpha Tau Medical reported?
Alpha Tau Medical reported successful delivery in all five cases of its first clinical trial and observed increased tumor responses in patients with higher radium-224 levels.
What clinical trial is Alpha Tau Medical currently running?
Alpha Tau Medical is running a safety and feasibility trial to treat advanced pancreatic cancer with Alpha DaRT at two university hospitals in Montreal, Canada.
What is the significance of the breakthrough technology used by Alpha Tau Medical?
The breakthrough technology utilizes alpha radiation to deliver highly potent and conformal radiotherapy for the treatment of solid tumors.
What are some upcoming milestones for Alpha Tau Medical in 2024?
Alpha Tau Medical plans to report financial results for the quarter ended March 31, 2024, and continue advancing its clinical trials to broaden the use of Alpha DaRT across various indications.
Alpha Tau Medical Ltd. Warrant